Brokers Issue Forecasts for Cencora’s Q2 Earnings (NYSE:COR)

Cencora, Inc. (NYSE:COR) – Leerink Partnrs lowered their Q2 2025 EPS estimates for Cencora in a report issued on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings of $4.08 per share for the quarter, down from their previous forecast of $4.23. The consensus estimate for Cencora’s current full-year earnings is $15.36 per share. Leerink Partnrs also issued estimates for Cencora’s Q4 2025 earnings at $3.82 EPS.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%.

A number of other equities research analysts have also weighed in on COR. UBS Group lifted their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Barclays lifted their target price on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company increased their price target on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Stock Down 0.7 %

Shares of NYSE:COR opened at $246.25 on Monday. The stock’s 50-day moving average is $238.94 and its 200 day moving average is $236.90. The company has a market cap of $47.59 billion, a PE ratio of 35.03, a P/E/G ratio of 1.49 and a beta of 0.49. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.53. Cencora has a 1 year low of $214.77 and a 1 year high of $262.26.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s payout ratio is 31.29%.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares of the company’s stock, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock valued at $17,790,912 in the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Dynamic Advisor Solutions LLC lifted its holdings in Cencora by 15.2% in the third quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company’s stock valued at $262,000 after acquiring an additional 154 shares during the period. Valeo Financial Advisors LLC lifted its stake in shares of Cencora by 5.0% in the 3rd quarter. Valeo Financial Advisors LLC now owns 1,645 shares of the company’s stock worth $370,000 after purchasing an additional 79 shares during the period. Gateway Investment Advisers LLC boosted its holdings in shares of Cencora by 9.0% in the third quarter. Gateway Investment Advisers LLC now owns 4,388 shares of the company’s stock worth $988,000 after buying an additional 364 shares during the last quarter. Ritholtz Wealth Management boosted its holdings in shares of Cencora by 0.8% in the third quarter. Ritholtz Wealth Management now owns 10,560 shares of the company’s stock worth $2,377,000 after buying an additional 82 shares during the last quarter. Finally, Retirement Planning Group LLC bought a new stake in Cencora during the third quarter valued at approximately $251,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.